Compare Natera Inc. Common Stock (NTRA) vs Southern Company (SO) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

Southern Company (SO) trades at $88.11, up 1.23% on the day, with a mixed technical outlook showing a bullish overall signal but bearish oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q3 2026 results pending. Revenue and net income are projected to grow in 2026, supported by a 15.43% net income margin. Analyst sentiment is cautious with a 32.35% buy rating, but the consensus price target of $96.38 suggests upside potential. Recent news highlights data center demand and dividend stability, though near-term cash flow pressure from high capital expenditures is a concern.

The outlook for SO is balanced, with long-term growth driven by utility demand and data center contracts, but near-term risks include capital expenditure pressures and potential data breach impacts. The stock offers a stable dividend and is positioned for gradual appreciation if earnings continue to outperform, yet investors should monitor cash flow trends and regulatory developments.